Bilcare Limited has informed the Exchange about the Redemption of Preference Shares held by the Company in Caprihans India Limited.
BI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Bilcare's board on February 12, 2026 approved unaudited Q3 FY26 results (quarter ended December 31, 2025). On a consolidated basis, the company reported a total income of Rs.186.46 crores and a net loss of about Rs.12.81 crores for the quarter; nine-month losses stood near Rs.45.89 crores. Standalone results showed a small profit of Rs.2.71 crores on total income of Rs.7.27 crores. As part of corporate actions with subsidiary Caprihans India Limited (CIL), Bilcare will receive redemption of 2.80 crore (out of 16.66 crore) 0.1% redeemable preference shares by March 31, 2026, and will convert 18.70 lakh convertible warrants into equity shares by paying the remaining 75% amount of Rs.28.05 crores. The auditor (Patki and Soman, newly appointed mid-year) flagged a going concern uncertainty due to past operating losses, questioned the treatment of Rs.14.42 crores CSIR loan penal interest as a contingent liability, and noted ongoing SFIO investigation.
Continuing consolidated losses combined with auditor's going concern qualification and CSIR loan default concerns are negative for shareholder sentiment. However, the preference share redemption and warrant conversion into equity of subsidiary CIL may strengthen Bilcare's stake and provide modest cash inflow by end of FY26.